These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

185 related items for PubMed ID: 22638145

  • 1. Sustained remission of multicentric Castleman disease in children treated with tocilizumab, an anti-interleukin-6 receptor antibody.
    Galeotti C, Boucheron A, Guillaume S, Koné-Paut I.
    Mol Cancer Ther; 2012 Aug; 11(8):1623-6. PubMed ID: 22638145
    [Abstract] [Full Text] [Related]

  • 2. Sustained remission of severe Multicentric Castleman disease following multiagent chemotherapy and tocilizumab maintenance.
    Turcotte LM, Correll CK, Reed RC, Moertel CL.
    Pediatr Blood Cancer; 2014 Apr; 61(4):737-9. PubMed ID: 24019247
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Anti-interleukin-6 receptor antibody (tocilizumab) treatment of multicentric Castleman's disease.
    Matsuyama M, Suzuki T, Tsuboi H, Ito S, Mamura M, Goto D, Matsumoto I, Tsutsumi A, Sumida T.
    Intern Med; 2007 Apr; 46(11):771-4. PubMed ID: 17541233
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Two cases of idiopathic multicentric Castleman disease with nephrotic syndrome treated with tocilizumab.
    Furutera N, Fukunaga N, Okita J, Suzuki T, Suenaga Y, Oyama Y, Aoki K, Fukuda A, Nakata T, Uesugi N, Daa T, Hisano S, Shibata H.
    CEN Case Rep; 2021 Feb; 10(1):35-41. PubMed ID: 32715375
    [Abstract] [Full Text] [Related]

  • 8. Successful treatment with tocilizumab for refractory anemia and slowly progressive renal glomerulosclerosis in multicentric Castleman disease: A case report.
    Sugawara E, Sato T, Amasaki Y, Katsumata K.
    Medicine (Baltimore); 2022 Feb 25; 101(8):e28941. PubMed ID: 35212301
    [Abstract] [Full Text] [Related]

  • 9. Successful treatment of a patient with multicentric Castleman's disease who presented with thrombocytopenia, ascites, renal failure and myelofibrosis using tocilizumab, an anti-interleukin-6 receptor antibody.
    Kawabata H, Kotani S, Matsumura Y, Kondo T, Katsurada T, Haga H, Kadowaki N, Takaori-Kondo A.
    Intern Med; 2013 Feb 25; 52(13):1503-7. PubMed ID: 23812199
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Successful treatment of a mesangial proliferative glomerulonephritis with interstitial nephritis associated with Castleman's disease by an anti-interleukin-6 receptor antibody (tocilizumab).
    Otani N, Morishita Y, Oh I, Saito O, Takemoto F, Muto S, Kusano E.
    Intern Med; 2012 Feb 25; 51(11):1375-8. PubMed ID: 22687845
    [Abstract] [Full Text] [Related]

  • 12. Is tocilizumab a potential therapeutic option for refractory unicentric Castleman disease?
    Abid MB, Peck R, Abid MA, Al-Sakkaf W, Zhang Y, Dunnill GS, Staines K, Sequeiros IM, Lowry L.
    Hematol Oncol; 2018 Feb 25; 36(1):320-323. PubMed ID: 28401573
    [Abstract] [Full Text] [Related]

  • 13. Tocilizumab histologically improved AA renal amyloidosis in a patient with multicentric Castleman disease: A case report
.
    Yamada Y, Ueno T, Irifuku T, Nakashima A, Doi S, Ichinohe T, Masaki T.
    Clin Nephrol; 2018 Sep 25; 90(3):232-236. PubMed ID: 29701172
    [Abstract] [Full Text] [Related]

  • 14. The Cytokine Storm of Multicentric Castleman Disease.
    Fajgenbaum DC.
    Adv Exp Med Biol; 2024 Sep 25; 1448():459-467. PubMed ID: 39117833
    [Abstract] [Full Text] [Related]

  • 15. Down-regulation of hepcidin resulting from long-term treatment with an anti-IL-6 receptor antibody (tocilizumab) improves anemia of inflammation in multicentric Castleman disease.
    Song SN, Tomosugi N, Kawabata H, Ishikawa T, Nishikawa T, Yoshizaki K.
    Blood; 2010 Nov 04; 116(18):3627-34. PubMed ID: 20644113
    [Abstract] [Full Text] [Related]

  • 16. Interleukin-6 in idiopathic multicentric Castleman's disease after long-term tocilizumab.
    Akiyama M, Yasuoka H, Takeuchi T.
    Ann Hematol; 2017 Dec 04; 96(12):2117-2119. PubMed ID: 28861599
    [No Abstract] [Full Text] [Related]

  • 17. Anti-interleukin 6 receptor antibody tocilizumab reduces the level of serum hepcidin in patients with multicentric Castleman's disease.
    Kawabata H, Tomosugi N, Kanda J, Tanaka Y, Yoshizaki K, Uchiyama T.
    Haematologica; 2007 Jun 04; 92(6):857-8. PubMed ID: 17550864
    [Abstract] [Full Text] [Related]

  • 18. Tocilizumab for focal segmental glomerulosclerosis secondary to multicentric Castleman's disease.
    Ebisawa K, Masamoto Y, Tokushige J, Nishi H, Honda K, Hinata M, Toyama K, Nangaku M, Kurokawa M.
    Ann Hematol; 2019 Aug 04; 98(8):1995-1997. PubMed ID: 30761408
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. The Role of Interleukin-6 in Castleman Disease.
    Yoshizaki K, Murayama S, Ito H, Koga T.
    Hematol Oncol Clin North Am; 2018 Feb 04; 32(1):23-36. PubMed ID: 29157617
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.